Literature DB >> 22119102

Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis.

David Baker1, Sandra Amor.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is one of the major pre-clinical models of multiple sclerosis. Use of this model has led to some important observations that has benefited human health, but it must also be said that there are many poor-quality studies using EAE that add little to knowledge or understanding. The lack of quality of clinical trials in humans led to the introduction of publication guidelines that aimed to improve the quality and transparency of studies. Therefore, with a view of doing the same, the ARRIVE (Animals in research: Reporting in vivo experiments) guidelines were developed as a checklist of information required for publication of animal studies. Based on the ARRIVE guidelines, we provide guidance on acceptable data handling and indicate the minimal acceptable standard that should be adhered to when reporting and importantly refereeing all publications relating to EAE. This is designed to constructively improve the quality of published work and reduce the futile use of animals in research.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22119102     DOI: 10.1016/j.jneuroim.2011.11.003

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  27 in total

1.  High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis.

Authors:  B Oxombre; C Lee-Chang; A Duhamel; M Toussaint; M Giroux; M Donnier-Maréchal; P Carato; D Lefranc; H Zéphir; L Prin; P Melnyk; P Vermersch
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

Review 2.  Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.

Authors:  Gareth Pryce; Dieter R Riddall; David L Selwood; Gavin Giovannoni; David Baker
Journal:  J Neuroimmune Pharmacol       Date:  2014-12-24       Impact factor: 4.147

3.  Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis.

Authors:  Ana Gutiérrez-Franco; Herena Eixarch; Carme Costa; Vanessa Gil; Mireia Castillo; Laura Calvo-Barreiro; Xavier Montalban; José A Del Río; Carmen Espejo
Journal:  Mol Neurobiol       Date:  2016-10-06       Impact factor: 5.590

4.  Therapeutic Effect of IL-21 Blockage by Gene Therapy in Experimental Autoimmune Encephalomyelitis.

Authors:  Miguel Chillón; Carmen Espejo; Ángel Edo; Laura Calvo-Barreiro; Herena Eixarch; Assumpció Bosch
Journal:  Neurotherapeutics       Date:  2022-07-28       Impact factor: 6.088

5.  Involvement of calcitonin gene-related peptide and receptor component protein in experimental autoimmune encephalomyelitis.

Authors:  Claudia Sardi; Laura Zambusi; Annamaria Finardi; Francesca Ruffini; Adviye A Tolun; Ian M Dickerson; Marco Righi; Daniele Zacchetti; Fabio Grohovaz; Luciano Provini; Roberto Furlan; Stefano Morara
Journal:  J Neuroimmunol       Date:  2014-03-19       Impact factor: 3.478

Review 6.  Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal.

Authors:  Fernando Dangond; Alexis Donnelly; Reinhard Hohlfeld; Catherine Lubetzki; Susan Kohlhaas; Letizia Leocani; Olga Ciccarelli; Bruno Stankoff; Maria Pia Sormani; Jeremy Chataway; Federico Bozzoli; Francesco Cucca; Lisa Melton; Timothy Coetzee; Marco Salvetti
Journal:  Nat Rev Neurol       Date:  2021-01-22       Impact factor: 42.937

7.  Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis.

Authors:  Herena Eixarch; Laura Calvo-Barreiro; Carme Costa; Gemma Reverter-Vives; Mireia Castillo; Vanessa Gil; José Antonio Del Río; Xavier Montalban; Carmen Espejo
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 6.088

8.  Open science and reporting animal studies: who's accountable?

Authors:  Jonathan A Eisen; Emma Ganley; Catriona J MacCallum
Journal:  PLoS Biol       Date:  2014-01-07       Impact factor: 8.029

9.  Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.

Authors:  Jens Ingwersen; Til Menge; Britta Wingerath; Derya Kaya; Jonas Graf; Tim Prozorovski; Andreas Keller; Christina Backes; Markus Beier; Matthias Scheffler; Thomas Dehmel; Bernd C Kieseier; Hans-Peter Hartung; Patrick Küry; Orhan Aktas
Journal:  Ann Clin Transl Neurol       Date:  2014-12-05       Impact factor: 4.511

10.  Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis.

Authors:  Sofia Sisay; Gareth Pryce; Samuel J Jackson; Carolyn Tanner; Ruth A Ross; Gregory J Michael; David L Selwood; Gavin Giovannoni; David Baker
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.